Posted by Michael Wonder on 27 Apr 2023
First vaccine to protect older adults from respiratory syncytial virus (RSV) infection
26 April 2023 - EMA has recommended a marketing authorisation in the European Union for Arexvy (recombinant, adjuvanted), the first vaccine for active immunisation to protect adults aged 60 years and older against lower respiratory tract disease caused by respiratory syncytial virus (RSV).
Arexvy contains an engineered version of the RSV fusion surface glycoprotein.
